Literature DB >> 33488588

Epstein-Barr Virus and Systemic Autoimmune Diseases.

Gunnar Houen1,2, Nicole Hartwig Trier2.   

Abstract

Epstein-Barr Virus (EBV) is an extremely successful human herpes virus, which infects essentially all human beings at some time during their life span. EBV infection and the associated immune response results in production of antibodies (seroconversion), which occurs mainly during the first years of life, but may also happen during adolescence or later in life. Infection of adolescents can result in infectious mononucleosis, an acute serious condition characterized by massive lymphocytosis. Transmission of EBV mainly occurs through saliva but can rarely be spread through semen or blood, e.g. through organ transplantations and blood transfusions. EBV transmission through oral secretions results in infection of epithelial cells of the oropharynx. From the epithelial cells EBV can infect B cells, which are the major reservoir for the virus, but other cell types may also become infected. As a result, EBV can shuttle between different cell types, mainly B cells and epithelial cells. Moreover, since the virus can switch between a latent and a lytic life cycle, EBV has the ability to cause chronic relapsing/reactivating infections. Chronic or recurrent EBV infection of epithelial cells has been linked to systemic lupus erythematosus and Sjögren's syndrome, whereas chronic/recurrent infection of B cells has been associated with rheumatoid arthritis, multiple sclerosis and other diseases. Accordingly, since EBV can shuttle between epithelial cells and B cells, the systemic autoimmune diseases often occur as overlapping syndromes with symptoms and characteristic autoantibodies (e.g. antinuclear antibodies and rheumatoid factors) reflecting epithelial and/or B cell infection.
Copyright © 2021 Houen and Trier.

Entities:  

Keywords:  Epstein-Barr virus; antibodies; connective tissue disease; human herpes virus; systemic autoimmune diseases

Year:  2021        PMID: 33488588      PMCID: PMC7817975          DOI: 10.3389/fimmu.2020.587380

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  175 in total

Review 1.  The Epigenetic Life Cycle of Epstein-Barr Virus.

Authors:  Wolfgang Hammerschmidt
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 2.  The etiology of rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Thomas Häupl; Gerd R Burmester
Journal:  J Autoimmun       Date:  2020-01-22       Impact factor: 7.094

3.  Increased levels of Epstein-Barr virus DNA in lacrimal glands of Sjögren's syndrome patients.

Authors:  K Tsubota; H Fujishima; I Toda; S Katagiri; Y Kawashima; I Saito
Journal:  Acta Ophthalmol Scand       Date:  1995-10

Review 4.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

Review 5.  Environmental factors in the pathogenesis of primary Sjögren's syndrome.

Authors:  A Björk; J Mofors; M Wahren-Herlenius
Journal:  J Intern Med       Date:  2020-02-27       Impact factor: 8.989

6.  Epstein-Barr virus IL-10 engages IL-10R1 by a two-step mechanism leading to altered signaling properties.

Authors:  Sung Il Yoon; Brandi C Jones; Naomi J Logsdon; Bethany D Harris; Srilalitha Kuruganti; Mark R Walter
Journal:  J Biol Chem       Date:  2012-06-12       Impact factor: 5.157

7.  Comparison of Methods Used for the Diagnosis of Epstein-Barr Virus Infections in Children.

Authors:  Nilgun Kasifoglu; Semra Oz; Ener Cagri Dinleyici; Tercan Us; Ozcan Bor; Gul Durmaz; Yurdanur Akgun
Journal:  Pol J Microbiol       Date:  2018-03-09

8.  The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.

Authors:  Anna M Gram; Timo Oosenbrug; Marthe F S Lindenbergh; Christian Büll; Anouskha Comvalius; Kathryn J I Dickson; Joop Wiegant; Hans Vrolijk; Robert Jan Lebbink; Ron Wolterbeek; Gosse J Adema; Marieke Griffioen; Mirjam H M Heemskerk; David C Tscharke; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz; Rob C Hoeben; Maaike E Ressing
Journal:  PLoS Pathog       Date:  2016-04-14       Impact factor: 6.823

9.  Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients.

Authors:  Anette Holck Draborg; Noreen Sandhu; Nanna Larsen; Janni Lisander Larsen; Søren Jacobsen; Gunnar Houen
Journal:  J Immunol Res       Date:  2016-03-27       Impact factor: 4.818

10.  Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation.

Authors:  Suzan Fares; Katja Spiess; Emma T B Olesen; Jianmin Zuo; Sarah Jackson; Thomas N Kledal; Mark R Wills; Mette M Rosenkilde
Journal:  mBio       Date:  2019-01-15       Impact factor: 7.867

View more
  29 in total

1.  Chronic Active Epstein-Barr Virus Infection Indistinguishable from Autoimmune Hepatitis: A Case Report.

Authors:  Suguru Ikeda; Takaaki Sugihara; Takuya Kihara; Yoshiki Hoshino; Yukako Matsuki; Takakazu Nagahara; Kenji Oyama; Jun-Ichi Okano; Satoshi Kuwamoto; Yasushi Horie; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2022-04-13       Impact factor: 1.371

2.  Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.

Authors:  Gabriela M Escalante; Lorraine Z Mutsvunguma; Murali Muniraju; Esther Rodriguez; Javier Gordon Ogembo
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

3.  Involvement of age-associated B cells in EBV-triggered autoimmunity.

Authors:  Athanasios Sachinidis; Alexandros Garyfallos
Journal:  Immunol Res       Date:  2022-05-16       Impact factor: 4.505

4.  Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis.

Authors:  Nuno Sepúlveda; João Malato; Franziska Sotzny; Anna D Grabowska; André Fonseca; Clara Cordeiro; Luís Graça; Przemyslaw Biecek; Uta Behrends; Josef Mautner; Francisco Westermeier; Eliana M Lacerda; Carmen Scheibenbogen
Journal:  Front Med (Lausanne)       Date:  2022-06-24

5.  The Potential for EBV Vaccines to Prevent Multiple Sclerosis.

Authors:  Peter A Maple; Alberto Ascherio; Jeffrey I Cohen; Gary Cutter; Gavin Giovannoni; Claire Shannon-Lowe; Radu Tanasescu; Bruno Gran
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

Review 6.  COVID-19 Disease and Dermatomyositis: A Mini-Review.

Authors:  Jie Qian; Hui Xu
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

Review 7.  Epstein-Barr Virus and Neurological Diseases.

Authors:  Nan Zhang; Yuxin Zuo; Liping Jiang; Yu Peng; Xu Huang; Lielian Zuo
Journal:  Front Mol Biosci       Date:  2022-01-10

8.  COVID-19 Vaccine Could Trigger the Relapse of Secondary Hypersomnia.

Authors:  Min Wu; Shirley Xin Li; Pei Xue; Junying Zhou; Xiangdong Tang
Journal:  Nat Sci Sleep       Date:  2021-12-29

9.  Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation.

Authors:  Jeffrey E Gold; Ramazan A Okyay; Warren E Licht; David J Hurley
Journal:  Pathogens       Date:  2021-06-17

10.  New Evidence of Significant Association between EBV Presence and Lymphoproliferative Disorders Susceptibility in Patients with Rheumatoid Arthritis: A Systematic Review with Meta-Analysis.

Authors:  Ana Banko; Danijela Miljanovic; Ivana Lazarevic; Ivica Jeremic; Aleksa Despotovic; Milka Grk; Andja Cirkovic
Journal:  Viruses       Date:  2022-01-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.